[1]徐勤惠, 杨平平, 荣康泰, 等．胞壁酰二肽及其类似物对吞噬功能的影响[J]．中华微生物学和免疫学杂志, 1992, 12(5): 277-281．
[2]李奕平, 王 潇．核苷酸结合寡聚化结构域NOD样受体(NLRs)研究进展[J]．生物技术通报, 2013, 29(7): 36-40．
[3]SALEM M, SEIDELIN J B, ROGLER G, et al．Muramyl dipeptide responsive pathways in Crohn's disease: from NOD2 and beyond [J]．Cell Mol Life Sci, 2013, 70(18): 3391-3404．
[4]高其宏, 芮 景．细胞内模式识别受体 NOD2 蛋白的研究进展[J]．放射免疫学杂志, 2008, 21(5): 432-434．
[5]LAURO M L, D'AMBROSIO E A, BAHNSON B J, et al．Molecular recognition of muramyl dipeptide occurs in the leucine-rich repeat domain of NOD2 [J]．ACS Infect Dis, 2017, 3(4): 264-270．
[6]RIBIC R, PAUREVIC M, TOMIC S．Advances in desmuramyl peptide research [J]．Croat Chem Acta, 2019, 92(2): 153-161．
[7]李树新．胞壁酰二肽的神经免疫调节作用[J]．中国药理学通报, 1994, 10(1): 5-8．
[8]ANDO K, MORI K, CORRADINI N, et al．Mifamurtide for the treatment of nonmetastatic osteosarcoma [J]．Expert Opin Pharmacother, 2011, 12(2): 285-292．
[9]KRISHNA M E, GANNERU B, HALMATHUR M S K, et al．Novel muramyl peptide derivative compound, synthesis and uses thereof: US, 2018371023A1 [P]．2018-12-27．
[10]INOHARA N, OGURA Y, FONTALBA A, et al．Host recognition of bacterial muramyl dipeptide mediated through NOD2 implications for Crohn′s disease [J]．J Biol Chem, 2003, 278(8): 5509-5512．
[11]MAISONNEUVE C, BERTHOLET S, PHILPOTT D J, et al．Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants [J]．Proc Natl Acad Sci USA, 2014, 111(34): 12294-12299．
[12]AZUMA I．Review: inducer of cytokines in vivo: overview of field and romurtide experience [J]．Int J Immunopharmacol, 1992, 14(3): 487-496．
[13]YANGHZ,XUS,LIAOXY,et al．A novel immunostimulator, N2-[α-O-benzyl-N-(acetylmuramyl)-Lalanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-Llysine, and its adjuvancy on the hepatitis B surface antigen [J]．J Med Chem, 2005, 48(16): 5112-5122．
[14]CHEDID L A, PARANT M A, AUDIBERT F M, et al．Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity [J]．Infect Immun, 1982, 35(2): 417-424．
[15]CHENG W C, YOU T Y, TEO Z Z, et al．Further insights on structural modifications of muramyl dipeptides to study the human NOD2 stimulating activity [J]．Chem Asian J, 2020, 15(22): 3836-3844．
[16]PARANT M A, AUDIBERT F M, CHEDID L A, et al．Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs [J]．Infect Immun, 1980, 27(3): 826-831．
[17]GOBEC M, MLINARI?-RA??AN I, DOLENC M S, et al, Structural requirements of acylated Gly-L-Ala-D-Glu analogs for activation of the innate immune receptor NOD2 [J]．Eur J Med Chem, 2016, 116: 1-12．
[18]DANKLMALER J, HüNIG H．Synthesis of acyclic analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP)[J]．Liebigs Ann Chem, 1990, 1990(2): 145-150．
[19]KHAN F A, ULANOVA M, BAI B, et al．Design, synthesis and immunological evaluation of novel amphiphilic desmuramyl peptides [J]．Eur J Med Chem, 2017, 141: 26-36．
[20]CHEN K T, HUANG D Y, CHIU C H, et al．Synthesis of diverse N‐substituted muramyl dipeptide derivatives and their use in a study of human NOD2 stimulation activity [J]．Chemistry, 2015, 21(34): 11984-11988．
[21]FURUYA T, KUMAZAWA Y, TAKIMOTO H, et al．Immunostimulatory activity of 1-O-acylated muramyl dipeptides, with or without a 6-O-phosphoryl group, in aqueous form [J]．Int J Immunopharmacol, 1989, 11(1): 35-43．
[22]WILLEMS M M J H P, ZOM G G, MEEUWENOORD N, et al．Design, automated synthesis and immunological evaluation of NOD2-ligand-antigen conjugates [J]．Beilstein J Org Chem, 2013, 10(1): 1445-1453．
[23]LAZOR K M, ZHOU J H, DEMEESTER K E, et al．Synthesis and application of methyl N,O‐hydroxylamine muramyl peptides [J]．ChemBioChem, 2018, 20(11): 1369-1375．
[24]NAGAI Y, AKIYAMA K, KOTANI S, et al．Structural specificity of synthetic peptide adjuvant for induction of experimental allergic encephalomyelitis [J]．Cell Immunol, 1978, 35(1): 168-172．
[25]MESHCHERYAKOVA E A, MINEEV K S, VOLYNSKI P E, et al．GMDP: unusual physico-chemical and biological properties of the anomeric forms [J]．J Pept Sci, 2015, 21(9): 717-722．
[26]DURETTE P L, DORN C P, SHEN T Y, et al．Synthesis and immunoadjuvant activity of 2-acetamido-1,5-anhydro2-deoxy-3-O-[(R)-2-propanoyl-L-alanyl-D-isoglutamine]-D-glucitol (“1-deoxymuramoyl dipeptide”) and its 6-(2-behenoyloxyisobutyrate) [J]．Carbohydr Res, 1982, 108(1): 139-147．
[27]HASEGAWA A, HIOKI Y, KISO M, et al．Synthesis of 1-thio-N-acetylmuramoyl-L-alanyl-D-isoglutamine derivatives, and their biological activities．XX [J]．J Carbohyd Chem, 1982, 1(3): 317-323．
[28]ZEMLYAKOV A E, TSIKALOVA V N, AZIZOVA L R, et al．Synthesis and biological activity of aryl S-betaglycosides of 1-thio-N-acetylmuramyl-L-alanyl-Disoglutamine [J]．Bioorg Khim, 2008, 34(2): 245-251．
[29]HASEGAWA A, OKUMURA H, NISHIBORI K, et al．The chemical modification of the C-2 substituent in the sugar moiety of N-acetylmuramoyl-L-alanyl-D-isoglutamine, and the immunoadjuvant activities [J]．Carbohydr Res, 1981, 97(2): 337-345．
[30]RAYMOND J B, MAHAPATRA S, CRICK D C, et al．Identification of the namH gene, encoding the hydroxylase responsible for the N-glycolylation of the mycobacterial peptidoglycan [J]．J Biol Chem, 2005, 280(1): 326-333．
[31]MELNYK J E, MOHANAN V, SCHAEFER A K, et al．Peptidoglycan modifications tune the stability and function of the innate immune receptor NOD2 [J]．J Am Chem Soc, 2015, 137(22): 6987-6990．
[32]TSUJIMOTO M, KINOSHITA F, OKUNAGA T, et al．Higher immunoadjuvant activities of N-acetylD-glucosaminyl-(1-4)-N-acetylmuramyl-L-alanyl-Disoglutamine in comparison with N-acetylmuramyl-L-alanylD-isoglutamine [J]．Microbiol Immunol, 1979, 23(9): 933-936．
[33]NISHIMURA K, OKUMURA H, SAIKI I, et al．Activation of mouse peritoneal adherent cells with N-acyl muramyl dipeptide derivatives [J]．Infect Immun, 1985, 47(3): 665-669．
[34]ANDO S, TSUGE H, MAYUMI T．Preparation of influenza virosome vaccine with muramyl dipeptide derivative B30-MDP [J]．J Micorencapsul, 1997, 14(1): 79-90．
[35]WILLEMS M M J H P, ZOM G G, MEEUWENOORD N, et al．Lipophilic muramyl dipeptide-antigen conjugates as immunostimulating agents [J]．ChemMedChem, 2016, 11(2): 190-198．
[36]TADA H, AIBA S, SHIBATA K I．Synergistic effect of NOD1 and NOD2 agonists with Toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells [J]．Infect Immun, 2005, 73(12): 7967-7976．
[37]PAVOT V, ROCHEREAU N, RESSéGUIER J, et al．Cutting edge: new chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity [J]．J Immunol, 2014, 193(12): 5781-5785．
[38]MA Y, ZHAO N, LIU G．Conjugate (MTC-220) of muramyl dipeptide analog and paclitaxel prevents both tumor growth and metastasis in mice [J]．J Med Chem, 2011, 54(8): 2767-2777．
[39]WEN X M, ZHENG P R, MA Y, et al．Salutaxel, a conjugate of docetaxel and a muramyl dipeptide (MDP) analog, acts as multi-functional prodrug that inhibits tumor cell growth and metastasis [J]．J Med Chem, 2018, 61(4): 1519-1540．